drugset / Trial / NCT00451711
Intermittent Liposomal Amphotericin B Primary Prophylaxis
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this trial is to see which dose of liposomal amphotericin B is the safest when used as a preventer against invasive fungal infection in patients with acute leukaemia who are undergoing chemotherapy.
Timeline
- Start
- 2007-05
- Primary completion
- —
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amphotericin B | Unknown | 1 mg/kg | Intravenous |
| Subject | Amphotericin B | Unknown | 3 mg/kg | Intravenous |
| Subject | Amphotericin B | Unknown | 10 mg/kg | Intravenous |